Ipilimumab, monoclonal antibody against cytotoxic T-lymphocyte antigen-4 and, radiotherapy are commonly used to treat unresectable and metastatic melanoma. As a result of upregulation of immune system with ipilimumab, many immune-related adverse effects, such as dermatitis, colitis, hepatitis, and hypophysitis, have been previously reported in literature. Typically, these effects are treated with high-dose steroids and mostly heal up. Here, we report a case who was receiving radiotherapy due to metastatic malignant melanoma with atypical generalized rash, which was enlarged with concurrent ipilimumab treatment.
HodiFSO’DaySJMcDermottDF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med2010; 63: 711–723.
2.
BarkerCAPostowMA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys2014; 88: 986–997.
3.
MinkisKGardenBCWuS. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol2013; 69: 121–128.
4.
PostowMACallahanMKBarkerCA. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med2012; 366: 925–931.
5.
DemariaSKawashimaNYangAM. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res2005; 11: 728–734.
6.
WongRKBensadounRJBoers-DoetsCB. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer2013; 10: 2933–2948.
7.
ChambersCAKuhnsMSEgenJG. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Ann Rev Immunol2001; 19: 565–594.
8.
WeberJSO’DaySUrbaW. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol2008; 26: 5950–5956.
9.
MakerAVYangJCSherryRM. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother2006; 29: 455–463.
10.
WolchokJDNeynsBLinetteG. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol2010; 11: 155–164.
11.
JaberSHCowenEWHaworthLR. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol2006; 142: 166–172.
12.
GutzmerRWollenbergAUgurelS. Cutaneous side effects of new antitumor drugs: clinical features and management. Dtsch Arztebl Int2012; 109: 133–140.
13.
WeberJSK€ahlerKCHauschildA. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol2012; 30: 2691–2697.
14.
AgrawalSKaneJM IIIGuadagnoloBA. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer2009; 115: 5836–5844.
15.
BurmeisterBHHendersonMAAinslieJ. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol2012; 13: 589–597.
16.
KingsleyDP. An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol1975; 48: 863–866.
17.
TeulingsHETjinEPWillemsenKJ. Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis. Br J Dermatol2013; 168: 733–738.
18.
LugadeAAMoranJPGerberSA. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol2005; 174: 7516–7523.
19.
DemariaSNgBDevittML. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys2004; 58: 862–870.
20.
HinikerSMChenDSReddyS. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol2012; 5: 404–407.
21.
ConillCJorcanoSDomingo-DomenechJ. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res2007; 17: 304–309.
22.
GyorkiDEAinslieJJoonML. Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma—a retrospective single centre study. Melanoma Res2004; 14: 223–230.
23.
BarkerCAPostowMAKhanSA. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res2013; 1: 92–98.
